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a b s t r a c t
The mechanistic basis for the tissue speciﬁc expression of cholesterol elimination pathways is poorly
understood. To gain additional insight into this phenomenon we considered it of interest to investigate
if epigenetic mechanisms are involved in the regulation of the brain-speciﬁc enzyme cholesterol 24hydroxylase (CYP46A1), a key regulator of brain cholesterol elimination. We demonstrated a marked
time-dependent derepression of the expression of CYP46A1, in response to treatment with the potent histone deacetylase (HDAC) inhibitor Trichostatin A. The pattern of expression of the genes in the genomic
region surrounding CYP46A1 was found to be diametrically opposite in brain and liver. Intraperitoneal
injection of HDAC inhibitors in mice led to a signiﬁcant derepression of hepatic Cyp46a1 mRNA expression and tissue speciﬁc changes in Hmgcr and Cyp39a1 mRNA expression. These results are discussed in
the context of the phenomenology of tissue speciﬁc cholesterol balance.
Ó 2008 Elsevier Inc. All rights reserved.

Although all nucleated cells are capable of cholesterol synthesis,
their ability to do so varies over several orders of magnitude. In the
adult state most organisms have established a certain level of
tissue specialisation [1]. The rate of cholesterol synthesis and the
cholesterol content of a given tissue are not necessarily directly
related, e.g. the adult brain contains more than 25% of whole body
cholesterol but turns over only 0.03% of its cholesterol content
each day. This turnover is much lower than the developing brain
[1] where cholesterol rich myelin is being formed. The slow
turnover of brain cholesterol is in marked contrast to that in most
other organs [1,2]. The mechanistic basis for these differences is
unknown, although they are probably a result of the functional
isolation of brain and blood cholesterol [3–5].
According to current concepts, the synthesis and elimination of
cholesterol in the adult brain is compartmentalised—astroglial
cells are believed to be responsible for the majority of synthesis
in the adult brain while they contribute relatively little to brain
elimination. The neuron speciﬁc cytochrome P450 cholesterol
24-hydroxylase (CYP46A1) is responsible for the elimination of
about two thirds of the cholesterol synthesised by the brain [6,7].
Recently it was shown that deletion of this gene led to a reduction
in the rate of brain cholesterol synthesis while the level of brain
cholesterol was maintained [8]. Due to the importance of this
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enzyme for brain cholesterol balance we have previously investigated its transcriptional regulation [9], with an expectation that
a gene so important for brain cholesterol balance would be subject
to complex mechanisms of regulation. Surprisingly we found the
opposite—expression of CYP46A1 was insensitive to mechanisms
known to regulate the key genes in cholesterol synthesis and elimination, HMGCR and CYP7A1, respectively. However, there are several examples in the literature indicating that CYP46A1 can be
induced [10–12]. A recent study by Milagre et al. indicated that
members of the SP1 family of transcription factors might regulate
CYP46A1 [13].
We considered it of high importance to investigate if epigenetic
mechanisms are involved in the control of the expression of
CYP46A1. In this form of regulation, distinct patterns of gene
expression are inherited by chromatin modiﬁcations, such as
DNA and histone methylation, that do not involve changes in
DNA [14]. Using a combination of in vitro and in vivo approaches
we show that the expression of CYP46A1, as well as other cytochrome P450s involved in cholesterol homeostasis, are potently
regulated by histone acetylation status.
Materials and methods
Materials. Trichostatin A was obtained from Sigma or from
Invivogen. Valproate was from Apoteket AB (Stockholm, Sweden).
Adult brain total RNA was from Clontech. Adult liver RNA was a
generous gift from Dr. Eva Ellis. Cell culture reagents were from
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50 lg/ml BHT in phosphate-buffered saline, pH 7.4) in a glass tube
and the tissue was disrupted using a polytron homogeniser. Three
millilitres of chloroform:methanol (2:1, v:v) were added and the
samples were mixed by moderate vortexing. Samples were centrifuged at 5000g for 5 min to permit phase separation and the lower
organic phase was recovered. The aqueous phase was reextracted
ﬁve more times and the organic phases pooled. Lipids were extracted from liver by placing the entire liver directly into 10 volumes of chloroform:methanol (2:1, v:v) for 48 h. Extracts were
dried under argon, redissolved in ethanol and stored at 20 °C until required. Sterols were analysed by gas chromatography–mass
spectrometry as described [15].
Statistics. Gene expression data is expressed as mean ± range as
described in Livak [16]. Statistical comparisons were performed
using the 2-tailed Students t-test, with the exception of the
in vivo effects of histone deacetylase inhibitors on Cyp46a1 expression. In accordance with our hypothesis that this gene is derepressed by these agents a one-tailed Student’s t-test was used. A
P value of less than 0.05 was considered signiﬁcant.
Ethical aspects. All animal experiments were approved by the
local Animal Experimentation Ethics Committee.
Results
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Derepression of CYP46A1 expression by inhibition of histone
deacetylases
The mechanisms underscoring the ectopic expression of
CYP46A1 have yet to be established. We investigated if CYP46A1
expression was regulated by histone acetylation status. Treatment
of SH-SY5Y neuroblastoma cells with TSA, a potent inhibitor of histone deacetylation, lead to a marked time-dependent derepression
of CYP46A1 expression and essentially restored the expression of
CYP46A1 to that of neurons (Fig. 1A). This observation was replicated in HepG2 hepatoma cells (results not shown). To further validate these ﬁndings we also performed RT-qPCR on SH-SY5Y cells
treated with 0.5 lM TSA for 48 h and observed a highly signiﬁcant
150-fold increase in CYP46A1 expression (P < 0.00001) (Fig. 1B). For

Size

Invitrogen. Primers for PCR were from Cybergene AB or assays on
demand (Applied Biosystems, Carlsbad, CA).
Cell culture and treatment with Trichostatin A. Human SH-SY5Y
neuroblastoma cells were cultured in DMEM containing 10% foetal
calf serum, 1% Glutamax, 100 U/ml penicillin, and 100 lg/ml streptomycin (all from Invitrogen, Carlsbad, CA) in a humidiﬁed incubator at 5% CO2. Cells were seeded into 35 mm dishes and allowed to
recover overnight before any addition of reagent. In initial time
course experiments cells were exposed to TSA at a ﬁnal concentration of 0.5 lM. After 0, 0.5, 1, 2, 4, 8 and 24 h of incubation the
medium was removed and cells were scraped into 1 mL of Trizol
per dish (Invitrogen, Carlsbad, CA). Cell pellets in Trizol were frozen at 80 °C until required. Subsequently cells were seeded into
six well plates, allowed to recover and exposed to 0.5 lM TSA for
48 h. Cells were harvested and stored as described above.
Animal Experiment I—chronic effects of valproate treatment.
Six-week-old male C57/B6-J mice (n = 5) were injected intraperitoneally with 700 mg/kg Ergenyl (valproic acid) dissolved in physiological saline. Controls (n = 5) received an equal volume of vehicle.
Injections were continued for ﬁve days and performed between 10
and 11 am. On day six the animals were stunned with CO2 and
killed by cervical dislocation. The brain and liver were removed,
weighed, snap frozen in liquid nitrogen and stored at 80 °C until
required.
Animal Experiment II—acute effects of Trichostatin A treatment.
C57/B6-J mice (as above) were injected intraperitoneally with 0,
2, 5 or 10 mg/kg of TSA dissolved in DMSO and diluted in physiological saline to a ﬁnal DMSO concentration of 18%. The total volume injected was 250 lL. Two hours after injection mice were
stunned with CO2 and killed by cervical dislocation. The brain
and liver were removed, weighed, snap frozen in liquid nitrogen
and stored at 80 °C until required.
Animal Experiment III—chronic effects of Trichostatin A treatment.
Male C57/B6-J mice (n = 5) were injected intraperitoneally with
2 mg/kg TSA as described above. Controls (n = 5) received an equal
volume of vehicle. Injections were continued for nine days and performed between 7 and 8 am. On day nine, approximately three
hours following the last injection, the mice were stunned with
CO2 and killed by cervical dislocation. Brain and liver samples were
collected and stored as described above.
Gene expression analysis. Total RNA was puriﬁed from cell or tissue samples using Trizol (Invitrogen, Carlsbad, CA). cDNA was synthesised from 2 lg of total RNA using the High Capacity cDNA
ReverseTranscription Kit (Applied Biosystems, Foster City, CA).
Steady-state mRNA levels were estimated using either Taqman
probes or SYBR green chemistries (primer sequences available on
request). All assays were run on an ABI Prism 7000 Sequence
Detection System (Applied Biosystems; Foster City, CA). Estimation
of relative gene expression was performed using the comparative
threshold cycle method, using cyclophilin A and hypoxanthineguanine phosphoribosyl transferase (HPRT) as endogenous controls
for cell culture and tissue samples, respectively.
Long-range chromatin mapping. One microgram samples of human adult brain and liver total RNA were used as templates for ﬁrst
strand cDNA synthesis using Superscript III and random hexamers
(both from Invitrogen, Carlsbad, CA). RT-qPCR was performed
using the Power SYBR green kit and using HPRT as endogenous
control (primers available on request). Expression levels were calculated according to the comparative threshold cycle method using
liver as the reference tissue. The range of expression was calculated
by solving the expression 2 DDCt+S, where S is the sum of the
squared standard deviations (SSD) for each gene in each tissue,
which accounts for the variance in the expression of both HPRT
and the target gene in each tissue.
Lipid extraction and analysis. Approximately 10 mg of brain tissue was added to 1 mL homogenisation buffer (5 mM EDTA,
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Fig. 1. Derepression of cholesterol 24-hydroxylase by histone deacetylase inhibition. (A) SH-SY5Y cells were treated with 0.5 lM of trichostatin A and gene
expression was evaluated by reverse transcription-PCR; (B) SH-SY5Y cells were
treated with 0.5 lM of trichostatin A for 48 h and gene expression was evaluated by
qPCR. Data is expressed as mean ± range.
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Fig. 2. Expression of genes in the genomic neighbourhood of cholesterol 24-hydroxylase is tissue speciﬁc. (A) The genomic structure of a 1Mb region centred at 14q32.1. The
orientation of the individual genes is indicated with an arrow and gene names are as follows: BCL11B—B-cell CLL/lymphoma 11B; SETD3—SET Domain Containing 3; CCNK—
Cyclin K; HHIPL1—Hedgehog interacting protein like- 1; CYP46A1—Cholesterol 24-hydroxylase; EML1—Echinoderm microtubule associated protein like-1; EVL—Enah/Vasplike; DEGS2—Degenerative spermatocyte homolog 2, lipid desaturase; YY1—YY-1 Transcription factor; (B) Comparative gene expression of this region in human brain and
liver. Gene expression in the liver is set to unity and a larger value indicates greater expression in the brain. Data is expressed as mean ± range.

reasons of comparison we also measured the expression levels of
other genes known to be important for brain sterol homeostasis.
There was no signiﬁcant effect on the expression of HMGCR, while
the expression of CYP7B1 was decreased and that of CYP27A1 increased (P < 0.0005 for both).
Long-range chromatin structure at CYP46A1
Previously published data indicated that the expression of
CYP46A1 is limited to the brain, with only trace amounts present
in other tissues [17]. To determine if the expression of genes in
the genomic neighbourhood of CYP46A1 were also coordinated in
different tissues we examined the expression of genes in a 1Mb region centred on CYP46A1 (see Fig. 2A). Using the brain and the liver
as model organs we show that in this region, CYP46A1 and DEGS2
were expressed at greater levels in the brain than in the liver
(see Fig. 2B). This data is consistent with previously presented data
on these genes, as well as public gene expression datasets (e.g. the
Allen Brain Atlas).
Effects of valproate treatment on cholesterol homeostasis
Given the potent effects of histone deacetylase inhibition on the
mRNA levels of CYP46A1 under in vitro conditions, we considered it
important to deﬁne if this ﬁnding could be replicated in vivo. Initially we used the anti-epilieptic drug valproic acid (VPA), which
is well known to have histone deacetylase inhibitor activity. Intraperitoneal injection of a high dose of VPA (700 mg/kg) for resulted
in a modest induction of the mRNA expression of Hmgcr and
Cyp46a1 in the liver, and Cyp46a1 in the brain (see Fig. 3A). However, treatment with VPA at this level lead to the death of three
of the treated mice, two at day three and one at day four indicating
that any observed changes in mRNA levels may be inﬂuenced by
the general toxic effects of VPA. A similar experiment with a lower
dose of VPA (350 mg/kg body weight) led to a similar pattern of
changes of mRNA with a signiﬁcant increase in Hmgcr and Cyp46a1
expression (P < 0.05 for both). There were no matching changes in
hepatic or cerebral steady-state sterol levels (results not shown).
To exclude the possibility that the capacity for downstream sterol
metabolism (i.e. 7a-hydroxylation 24S-hydroxycholesterol) may
have been altered by VPA treatment, we measured the mRNA
levels of Cyp39a1 in both the liver and brain. Surprising, we found

a 2-fold increase in expression of Cyp39a1 in the brain
(P < 0.01) and a 50% decrease in hepatic expression (P < 0.002)
(Fig. 3B).
Effects of TSA treatment on cholesterol homeostasis
In light of the abovementioned toxic effects of high dose VPA
treatment we decided to employ the potent histone deacetylase
inhibitor TSA. We initially studied the dose dependent effects of
TSA treatment in an acute model. IP injection of TSA to male mice
resulted in dose dependent increases in the expression of brain
Cyp46a1 and Cyp39a1. This was recapitulated in the liver with increases in hepatic Cyp46a1 and Cyp7b1 expression and decreases
in both Hmgcr and Cyp39a1 levels (Fig. 4A). Intriguingly, the response of female mice to the same regimen was markedly different
(results not shown).
We then treated animals with 2 mg/kg TSA for nine days. This
resulted in a small-but-signiﬁcant reduction in brain Hmgcr mRNA
expression (P < 0.05). No signiﬁcant change was observed in the
cerebral expression of Cyp46a1, Cyp39a1 or Cyp7b1 (Fig. 4B). The
situation in the liver was similar to that observed following VPA
treatment, with a 2.5-fold increase in hepatic Cyp46a1 expression.
In accordance with our hypothesis that inhibition of histone deacetylase increased the mRNA levels of Cyp46a1, this was signiﬁcant
following a one-tailed t-test (P < 0.05). Again, there were no measurable differences in the total brain or liver sterol levels (results
not shown).

Discussion
Previously we have shown that the activation of a reporter construct containing ﬁreﬂy luciferase under the control of 2.6 Kb of the
human CYP46A1 promoter was refractory to interventions known
to regulate other genes involved in cholesterol balance [9]. However, several groups have independently demonstrated the presence of ectopic expression of CYP46A1. The current study was
initiated to determine if epigentic mechanisms could be involved
in these phenomena.
The observation that TSA treatment potently derepressed
CYP46A1 expression supports our hypothesis that chromatin con-
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Fig. 3. Effects of valproate treatment on hepatic and cerebral gene expression in the mouse. (A) Dose dependent effects on the expression of Hmgcr and Cyp46a1. Treatment
with valproate led to dose dependent changes in the mRNA expression of Hmgcr and Cyp46a1 in the liver, and Cyp46a1 in the brain. (B) Divergent regulation of Cyp39a1
expression in brain and liver. Treatment with valproate lead to a 2-fold increase in expression of Cyp39a1 in the brain, while hepatic levels were reduced to approximately half
of the control value (Fig. 3b).

densation was important for the transcriptional activation of
CYP46A1. Examination of the relative expression of the genes in a
1 Mb genomic region centred on CYP46A1 revealed two areas with
markedly higher expression in the brain compared with the liver—
CYP46A1 and DEGS2. This ﬁnding is consonant with the idea that a
large genomic region is silenced in neurons. Taken together these
data provide support for the hypothesis that epigenetic mechanisms are involved in establishing the neuronal expression of
CYP46A1. Inspection of the CYP46A1 gene revealed two candidate
sites for the neuron restrictive silencing factor (NRSF), a transcription factor known to be involved in neuron speciﬁc gene expression [18]. In pilot studies we attempted to abrogate any effects of
NRSF on CYP46A1 expression using a dominant negative NRSF
mutant construct. However no signiﬁcant effect on CYP46A1 mRNA
levels was observed (results not shown).
The overall pattern of changes in the mRNA expression of
Cyp46a1 was remarkably consistent under a variety of different
treatment schemes, despite the difﬁculties in normalising gene
expression data following treatment with such a potent gene regulator [19]. A further complication is the pharmacokinetic proﬁle
of TSA—the plasma half-life of this compound in mice is 7–9 min
and available data indicates signiﬁcant and rapid hepatic metabolism, potentially to less active compounds [20]. The short half-life
may be part of the reason for the marked differences between the

acute and chronic TSA mediated regulation of selected genes e.g.
Cyp7b1.
An intriguing ﬁnding of our investigations into the acute effects
of TSA was the ﬁnding of gender speciﬁc responses to effects of the
treatment. It has been established that hepatic expression of
Cyp7b1 is greater in male mice, whereas that of Cyp39a1 is greater
in females [21,22]. This pattern appears to be potentiated by TSA
treatment, at least under acute conditions, suggesting that epigenetic mechanisms may be a general regulator of sexually dimorphic cytochrome P450 expression (results not shown).
A surprising ﬁnding was the detection of signiﬁcant levels of
Cyp39a1 in the brain. This cytochrome P450, which is a 7a-hydroxylase highly speciﬁc for 24S-hydroxycholesterol, was originally
cloned as liver speciﬁc species [21]. Subsequent investigations have
identiﬁed Cyp39a1 mRNA or protein in brain or the non-pigmented
epithelium of the retina [23,24]. To the best of our knowledge, this
is the ﬁrst demonstration of pharmacological regulation of CYP39A1.
At present the reason for the diametrically opposite regulation in
brain and liver is unclear. However, this provides a plausible explanation for absence of changes in brain 24S-hydroxycholesterol—
induction of the CYP39A1 within the brain may theoretically lead
to intracerebral production of 7a,24S-dihydroxycholesterol and
mask any increase in 24S-hydroxycholesterol content. An analogous
situation may exist for 27-hydroxycholesterol.
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Fig. 4. Effects of trichostatin A treatment on hepatic and cerebral gene expression in the mouse. (A) Acute treatment with increasing doses of Trichostatin A leads to marked
dose dependent changes in gene expression. Hepatic mRNA levels of Cyp46a1 and Cyp7b1 were markedly increased while Cyp39a1 and Hmgcr levels were suppressed. In the
brain Cyp46a1 was increased while Cyp39a1 mRNA levels were again reduced. There were no consistent effects on the cerebral expression of either Hmgcr or Cyp7b1. (B)
Chronic treatment with 2 mg/kg of trichostatin A leads to modest changes in hepatic and gene expression. In consonance with previous results there was an increase in
hepatic Cyp46a1 mRNA levels was observed (P < 0.05) with no signiﬁcant change in the brain. Conversely, there was a small-but-signiﬁcant reduction in brain Hmgcr mRNA
levels (P < 0.05) while hepatic levels were unchanged.

It has previously been shown that some genes involved in cholesterol synthesis are epigenetically regulated [25]. The current
data supports the contention that epignetic mechanisms are of
general importance for the regulation of the transcription of cytochrome P450s involved in metabolism and elimination of cholesterol via oxidative mechanisms.
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